Hemoglobin Normalization Studies

Hsu C.Y. , McCulloch C.E. , Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13(2): 504–10.

Collins A.J. , Li S. , St Peter W. , Ebben J. , Roberts T. , Ma J. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12(11): 2465–73.

Xue J.L. , St Peter W.L. , Ebben J.P. , Everson S.E. , Collins A.J. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40(6): 1153–61.

Regidor D.L. , Kopple J.D. , Kovesdy C.P. , Kilpatrick R.D. , McAllister C.J. , Aronovitz J. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17(4): 1181–91.

Li S. , Foley R.N. , Collins A.J. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65(5): 1864–9.

Besarab A. , Bolton W.K. , Browne J.K. , Egrie J.C. , Nissenson A.R. , Okamoto D.M. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see Comments]. N Engl J Med 1998; 339(9): 584–90.

Parfrey P.S. , Foley R.N. , Wittreich B.H. , Sullivan D.J. , Zagari M.J. , Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16(7): 2180–9.

Roger S.D. , McMahon L.P. , Clarkson A. , Disney A. , Harris D. , Hawley C. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15(1): 148–56.

Levin A. , Djurdjev O. , Thompson C. , Barrett B. , Ethier J. , Carlisle E. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46(5): 799–811.

Singh A.K. , Szczech L. , Tang K.L. , Barnhart H. , Sapp S Wolfson M. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355(20): 2085–98.

Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22(2): 309–12.

Singh A.K. , Szczech L. , Tang K.L. , Barnhart H. , Sapp S. , Wolfson M. Anaemia of CKD—the CHOIR study revisited. Nephrol Dial Transplant 2007; [Epub ahead of print].

Clinical Study Report. 2006. Available from URL: http://download.veritasmedicine. com/PDF/CR004588_CSR.pdf

Furuland H. , Linde T. , Ahlmen J. , Christensson A. , Strombom U. , Danielson B.G. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18(2): 353–61.

Grzeszczak W. , Sulowicz W. , Rutkowski B. , de Vecchi A.F. , Scanziani R. , Durand P.Y. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 2005; 20(5): 936–44.

Mahajan S. , Boulton H. , Gokal R. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. J Nephrol 2004; 17(5): 687–92.

Macdougall I.C. , Matcham J. , Gray S.J. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003; 18(3): 576–81.

House A.A. , Pham B. , Page D.E. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant 1998; 13(7): 1763–9.

Snyder J.J. , Foley R.N. , Gilbertson D.T. , Vonesh E.F. , Collins A.J. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 2004; 15(1): 174–9.

Kaufman J.S. , Reda D.J. , Fye C.L. , Goldfarb D.S. , Henderson W.G. , Kleinman J.G. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339(9): 578–83.

FDA. Information for Healthcare Professionals: Erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. 2007. Available at URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm [Accessed 3 September 2007]

Phrommintikul A. , Haas S.J. , Elsik M. , Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369(9559): 381–8.